Market Overview

Research and Markets: Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2012


Research and Markets ( has announced the addition of Global Markets Direct's new report "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2012" to their offering.

This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA).


- A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA).

- A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Spinal Muscular Atrophy (SMA) therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Involved in Spinal Muscular Atrophy (SMA) Therapeutics Development

- F. Hoffmann-La Roche Ltd.

- Isis Pharmaceuticals, Inc.

- Oxford BioMedica plc

- Paratek Pharmaceuticals, Inc.

- Repligen Corporation

- Trophos SA

- Nexgenix Pharmaceuticals, LLC

- Prosensa Therapeutics B.V.

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

View Comments and Join the Discussion!